Abstract 115P
Background
Trifluridine/tipiracil (lonsurf) and regorafenib are standard of treatment in patients with chemo-refractory metastatic colorectal cancer (mCRC). Our study aimed to investigate the impact of sidedness on survival in patients with mCRC treated with lonsurf or regorafenib.
Methods
Patients who were diagnosed with mCRC and treated with lonsurf or regorafenib between 2015 and 2022 were retrospectively identified from Taiwan National Health Insurance Research Database and Taiwan Cancer Registry. Propensity score matching was used to reduce the selection bias. The oncologic outcomes were presented with time to treatment failure (TTF) and overall survival (OS).
Results
A total of 4665 patients were identified. After matching, 752 patients were analyzed for outcomes comparison, including 376 patients in each group. In general, median TTF and OS were 1.9 months versus 2.0 months (p = 0.701)and 9.1 months versus 7.0 months (p = 0.008) in lonsurf and regorafenib, respectively. Patients were stratified by sidedness, including 297 left side mCRC in each group and 79 right side mCRC in each group. For patients with left side colon, median TTF and OS were 1.9 months versus 2.0 months (p = 0.178) and 10.2 months versus 7.8 months (p = 0.006) in lonsurf and regorafenib, respectively, while for patients with right side colon, median TTF and OS were 1.8 months versus 1.8 months (p = 0.390) and 7.8 months versus 6.0 months (p = 0.011) in lonsurf and regorafenib, respectively.
Conclusions
Lonsurf provided a longer survival over regorafenib in mCRC patients regardless of sidedness of primary tumor location.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
472P - Risk of recurrence and optimal adjuvant treatment in invasive lung adenocarcinomas manifesting as radiological part-solid nodules
Presenter: Yang Wo
Session: Poster Display
Resources:
Abstract
473P - Treatment (tx) patterns in resectable stage IA–IIIA non-small cell lung cancer (NSCLC) in China: Subgroup analysis of a global real-world (rw) study
Presenter: Chih-Chi Yang
Session: Poster Display
Resources:
Abstract
474P - The efficacy of image guided coil localisation for surgical resection of undiagnosed solitary lung nodule
Presenter: Jun Rey Leong
Session: Poster Display
Resources:
Abstract
475P - 5-year overall survival and disease free survival outcome between lobectomy and segmentectomy for early stage lung cancer in a mixed Asian population
Presenter: Jianye Chen
Session: Poster Display
Resources:
Abstract
478P - Peri-operative risks in curative lung resection of early stage primary lung cancer patients above 70 years old in a mixed Asian population
Presenter: Ian Goh
Session: Poster Display
Resources:
Abstract
480P - Aumolertinib as adjuvant therapy for resectable stage I-III EGFR-mutant NSCLC: Also effective in EGFR co-mutation
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
481P - Comparative analysis of three NGS platforms assessing tumor mutational burden and mutational landscape in resectable non-small cell lung cancer
Presenter: Jii Bum Lee
Session: Poster Display
Resources:
Abstract
482P - Prevalence of EGFR mutations (EGFRm) and its subtypes in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR Singapore cohort
Presenter: Puey Ling Chia
Session: Poster Display
Resources:
Abstract
483P - Genetic profiles and evolutionary trajectory of early stage lung adenocarcinoma (AAH, AIS, MIA and IAC) revealed by multiplex sequecing
Presenter: lixuan lin
Session: Poster Display
Resources:
Abstract
484P - Treatment (tx) patterns and outcomes in resectable early-stage EGFR-mutated (EGFRm) NSCLC in South Korea: Subgroup analysis of a global real-world (rw) study
Presenter: Myung-Ju Ahn
Session: Poster Display
Resources:
Abstract